ENYO Pharma
Manufacturing · France · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Bioserra 1 60 Av. Rockefeller Bâtiment B...Phone Number
+33 437700219Website
www.enyopharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About ENYO Pharma
NYO is a clinical-stage biopharmaceutical company headquartered in Lyon (France) and developing proprietary drug candidates to improve quality of life and avoid end stage renal disease and dialysis/transplantation for patients with rare and common kidney diseases. Since its inception ENYO collected extensive phase I/II clinical data through nine completed clinical studies with ca. 400 subjects.Explore more
ENYO Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ENYO Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when ENYO Pharma launches new products
Website visits: Recent activity has been detected on your website
Check if ENYO Pharma has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once ENYO Pharma has new funding data
Congratulate Masked Content for being promoted to Masked Content at ENYO Pharma
ENYO Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if ENYO Pharma is spiking on competitors!
Earning: See what the market has to say on ENYO Pharma recently announced quarterly report
Click to see if ENYO Pharma had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
ENYO Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
ENYO Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about ENYO Pharma.
ENYO Pharma financials insights
Gather financial insights about ENYO Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$24M
Grant
$2.7M
2018
Series B
$40M
2025
Series C
$37M
ENYO Pharma Tech Stack
A closer look at the technologies used by ENYO Pharma
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Funding
Funding
ENYO Pharma News & Media
ENYO Pharma Announces a €39 Million Series C Financing and FDA Clearance to Advance Vonafexor in a Phase 2 Clinical Trial for Patients With Alport Syndrome
LYON, France--(BUSINESS WIRE)--ENYO Pharma (“ENYO”) announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical study of Vonafexor, a highly selective FXR agonist, for the treatment of Alport Syndrome. Furthermore, ENYO announced the first closing of a 39 million € Series C equity financing, positioning ENYO as an emerging biotechnology company in the field of renal diseases. TheENYO Pharma annonce deux présentations de données sur Vonafexor lors du Liver Meeting organisé par l'American Association for the Study of Liver Diseases (AASLD)
LYON, France--(BUSINESS WIRE)--ENYO Pharma (ENYO), une société biotechnologique privée de stade clinique qui développe des candidats médicaments innovants, a annoncé aujourd'hui que deux résumés sur Vonafexor ont été acceptés: l'un sous la forme d'une présentation orale et l'autre, d'une affiche, dans le cadre du prochain The Liver Meeting® 2021, organisé par l'American Association for the Study of Liver Diseases (AASLD), qui se tiendra du 12 au 15 novembre 2021. Ces présentations font suite àENYO Pharma Announces Two Vonafexor Data Presentations at AASLD The Liver Meeting
LYON, France--(BUSINESS WIRE)--ENYO Pharma (ENYO), a private clinical stage biotechnology company developing innovative drug candidates, today announced that two abstracts on Vonafexor were accepted one as oral presentation and one as poster during the upcoming The Liver Meeting® 2021, organized by the American Association for the Study of Liver Diseases (AASLD) on November 12-15, 2021. This follows two press releases published late July 2021 by ENYO: - Positive Vonafexor results for the LIVIFYENYO Pharma annonce les premiers résultats intermédiaires du Vonafexor (EYP001) à 16 semaines dans deux études de phase 2a en cours chez des patients atteints d'hépatite B chronique
LYON, France--(BUSINESS WIRE)--ENYO Pharma (ENYO), une société privée de biotechnologie au stade clinique et développant des candidats-médicaments innovants, a annoncé aujourd'hui des données de preuve de concept positives issues de l'étude EYP001-203 de Vonafexor en association avec le peg-Interféron chez des patients virémiques atteints d'hépatite B chronique (CHB). Vonafexor (EYP001) a atteint le critère d'évaluation principal consistant à abaisser l'HBsAg, un biomarqueur clé de l'activité v
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ENYO Pharma
Sign Up For FreeTo access detailed company insights
NYO is a clinical-stage biopharmaceutical company headquartered in Lyon (France) and developing proprietary drug candidates to improve quality of life and avoid end stage renal disease and dialysis/transplantation for patients with rare and common kidney diseases. Since its inception ENYO collected extensive phase I/II clinical data through nine co... Read More
